Cimaglermin alfa

Drug Profile

Cimaglermin alfa

Alternative Names: CGF-2; GGF-2 - Acorda; Glial growth factor 2 - Acorda; Neuregulin 1 protein; Neuregulin 1β3; NRG1 protein; Recombinant human glial growth factor-2 (rhGGF 2) - Acorda Therapeutics; rhGGF2 - Acorda

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Developer Acorda Therapeutics
  • Class Growth factors; Heart failure therapies; Nerve tissue proteins; Neuregulins
  • Mechanism of Action Epidermal growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure
  • Preclinical Neurological disorders; Stroke

Most Recent Events

  • 01 Jul 2016 Acorda Therapeutics completes a phase Ib trial for Heart failure in USA (NCT01944683)
  • 30 Jul 2015 Adverse events data from a phase Ib trial in Heart failure released by Acorda
  • 02 Jun 2015 The US FDA places a clinical hold on phase Ib trial in Heart failure in USA (Acorda Therapeutics, Form 8-K, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top